Intellia Therapeutics presented top-line data from its phase III HALO study in HAE during the Bank of America Global Healthcare Conference on May 12. The results showed substantial clinical benefits for patients with the condition.
Chief financial officer Edward Dulac described the findings as highly encouraging during the session. All patients achieved meaningful clinical benefit, with 62 percent remaining attack-free and therapy-free at the end of the 28-week primary observation period. Attack rate reductions reached the high upper 80 percent range, outcomes that Dulac said match or surpass prior reports in the field.
